Tropical Journal of Pharmaceutical Research
Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria
Vol. 13, No. 8, 2014, pp. 1195-1198
Bioline Code: pr14165
Full paper language: English
Document type: Research Article
Document available free of charge
Tropical Journal of Pharmaceutical Research, Vol. 13, No. 8, 2014, pp. 1195-1198
© Copyright 2014 - Tropical Journal of Pharmaceutical Research
Pegylation of Nanoliposomal Paclitaxel Enhances its Efficacy in Breast Cancer|
Esfahani, Maedeh Koohi Moftakhari; Alavi, Seyed Ebrahim; Akbarzadeh, Azim; Ghassemi, Soheil; Saffari, Zahra; Farahnak, Maryam & Chiani, Mohsen
Purpose: To encapsulate paclitaxel into nanoliposomes, followed by pegylatation, in order to improve
its therapeutic index and reduce side effects in breast cancer.
Methods: In order to prepare nanoliposomal paclitaxel, varying ratios of phosphatidylcholine,
cholesterol and paclitaxel were mixed and the formulations pegylated with poly-ethylene glycol 2000
(PEG 2000) to enhance stability, efficiency, as well as solubility. The mean diameter of nanoliposomal
paclitaxel and pegylated nanoliposomal paclitaxel were measured by Zeta sizer device and release of
paclitaxel from both formulations was determined within 28 h by dialysis method. The cytotoxicity of
nanoliposomal and pegylated nanoliposomal paclitaxel was evaluated using 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay.
Results: The mean diameter of nanoliposomal paclitaxel and pegylated nanoliposomal paclitaxel was
421.4 and 369.1 nm, respectively, while encapsulation efficiency was 91.3 ± 5.7 and 95.2 ± 6.3 %,
respectively. Paclitaxel released from both formulations in 28 h was 5.53 and 5.02 %, respectively. The
cytotoxicity of pegylated nanoliposomal paclitaxel was significantly (p <0.05) greater than that of
nanoliposomal paclitaxel (their IC50 = 79.8±2.9 and 86.25±3.4 µg/ml, respectively).
Conclusion: The release pattern and cytotoxicity of pegylated nanoliposomal paclitaxel show that the
formulation is superior to nanoliposomal paclitaxel. Furthermore, the mean particle size of pegylated
nanoliposome is smaller than that of the non-pegylated preparation.
Paclitaxel; Nanoliposome; Breast cancer; Pegylation; Drug delivery; Cytotoxicity
Alternative site location: http://www.tjpr.org